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Abstract
The purpose of this study was to investigate the change in plasma protein expression in first episode schizophrenia after an
8-week treatment with risperidone, and to explore potential biomarkers for metabolic side effects associated with
risperidone treatment. Eighty first-episode schizophrenia patientswere enrolled in the study. Fifteen of the 80 patients were
randomly selected to undergo proteomic analysis. Plasma proteins were obtained before and after the 8-week risperidone
treatment, and measured using two-dimensional gel electrophoresis (2-DE), Matrix-Assisted Laser Desorption/Ionization
Time of Flight Mass Spectrometry(MALDI-TOF/TOF) and peptide mass fingerprinting.Proteins with the highest fold changes
after risperidone treatment were then measured for all 80 patients using enzyme linked immunosorbent assay (ELISA). The
relationship between changes in plasma protein levels and changes in metabolic parameters after risperidone treatment
was examined. In 15 randomly selected patients, approximately 1,500 protein spots were detected in each gel by 2-DE. Of
those proteins, 22 spots showed significant difference in abundance after risperidone treatment (p’s,0.05). After MALDI-
TOF peptide mass fingerprinting, apolipoprotein A-I (APOA-I) and Guanine Nucleotide Binding Protein, Alpha Stimulating
(GNAS), were found to have the highest fold changes.The content of APOA-I was significantly increased, and the content of
GNAS was significantly decreased after risperidone treatment (p’s,0.05). The analysis in the entire study sample showed
similar findings in changes of APOA-I and GNAS after risperidone treatment. Further analysis showed significant
relationships between changesin APOA-1 and changes in triglyceride, total cholesterol, and body mass index after
controlling for age, gender and family history of diabetes. Similar analysis showed a trend positive relationship between
changes in GNAS and changes in BMI. Using proteomic analysis, the study suggested that APOA-I might be a novel
biomarkers related to metabolic side effects in first episode schizophrenia treated with risperidone.
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Introduction
Risperidone is a commonly used agent for schizophrenia
treatment. However, risperidone is associated with significant
metabolic side effects, including weight gain [1], impaired glucose
tolerance and elevated lipid levels [2–4]. These adverse reactions
increase the risk for cardiovascular disease and reduce treatment
compliance. The mechanism of metabolic problems related to
antipsychotic treatment remains largely unknown at this time.
Proteomics uses a large-scale, automatic analysis of cellular
protein expression profiles with both high-throughput and high-
sensitivity. Proteomic analysis has been widely used to identify
biomarkers for the diagnosis and treatment response of various
diseases [5]. Previous studies using proteomic analysis have
identified several proteins that are possible novel biomarkers
related to the development of metabolic problems, such as obesity,
diabetes and elevated lipids, in the general population [6–8].
Using proteomic analysis, the present study was to investigate
the change in plasma protein expression in first episode
schizophrenia after an 8-week treatment with risperidone, and to
identify potential biomarkers for metabolic side effects associated
with risperidone treatment.
Materials and Methods
Subjects
The study was carried out in accordance with The Code of
Ethics of the World Medical Association (Declaration of Helsinki)
for experiments involving humans. This study was conducted at
the inpatient units of Henan Mental Hospital between January
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2011 and December 2011. All subjects gave their written informed
consent prior to participation in this study after fully understood
the purpose and procedures. The patients’ capacity to sign the
informed consent was based on the judgment of their clinician. If a
patient was unable to give informed consent, it was signed by his/
her caregiver. All study protocols were approved by the
Institutional Review Board of Henan Mental Hospital. Inpatients
with first episode schizophrenia were recruited from Henan
Mental Hospital. The diagnosis of schizophrenia was determined
by a research psychiatrist (X.L.) using the Structured Clinical
Interview for DSM-IV Axis I Disorders. The inclusion criteria
included: 1) age 18 to 45 years; 2) disease duration less than 2
years. Patients were excluded if they had: 1) prior antipsychotic
treatment; 2) previous history of alcohol or other substance use; 3)
additional psychiatric diagnosis other than schizophrenia; 4)
certain medical conditions including acute infection, heart disease,
epilepsy, hepatic or renal diseases, diabetes, aplastic anemia,
asthma or autoimmune diseases; 5) female patients who were
pregnant or lactating. A complete medical history was obtained
from all subjects. All subjects were treated in the same hospital,
underwent daily physical examination and weekly routine
laboratory tests. All patients had the same standard diet provided
by the hospital, and structured daily light-to-moderate physical
activity (30 minutes, led by nursing staff).
After baseline assessment, all patients were treated with
risperidone with the dose ranging from 4 mg to 6 mg per day
based on the clinical judgment of treating psychiatrists. No other
medication was allowed during the study except benzodiazepines
for insomnia and anticholinergic agents for dystonia reaction.
Assessment
Symptoms of schizophrenia were assessed using the Positive and
Negative Syndrome Scale (PANSS). The PANSS was assessed
before and after 8 weeks of risperidone treatment. Family history
of psychiatric disorders including both Axis I and Axis II disorders
was obtained from both patients and their family members if they
were available. For all subjects, weight (kg), height (m), plasma
glucose (mmol/l) and lipid levels (mmol/l) were measured before
and after treatment. Body mass index (BMI) (kg/m2) was
calculated based on weight and height. Glucose oxidase was used
Table 1. Demographic characteristics of the study sample (N= 80).
Mean±SD Range
Age(years) 2465 19–36
Disease duration (months) 1165 1–23
Age of illness onset (years) 2364 18–34
N %
Gender
Male 42 52.5
Female 38 47.5
Family history of psychiatric disorders
Yes 7 8.75
No 73 91.25
Benzodiazepine
Yes 9 11.25
No 71 88.75
doi:10.1371/journal.pone.0093902.t001
Table 2. Clinical measures before and after 8 weeks of risperidone treatment (N = 80).
Before treatment After treatment t value p value
Weight (Kg) 62.05610.53 64.06610.17 28.90 ,0.001
BMI (kg/m2) 22.2461.86 22.9961.8 29.08 ,0.001
blood glucose (mmol/l) 4.7460.45 4.7660.43 21.44 0.124
triglyceride (mmol/l) 0.7960.20 0.8160.16 23.11 0.001
cholesterol (mmol/l) 4.4560.48 4.4860.43 23.49 0.001
LDL (mmol/l) 2.0760.50 2.1160.47 21.33 0.189
HDL (mmol/l) 1.276.015 1.2660.15 2.05 0.043
PANSS total 71.8367.18 53.0968.00 28.47 ,0.001
PANSS positive 20.7864.97 13.7162.89 13.30 ,0.001
PANSS negative 15.0064.43 10.6462.12 9.88 ,0.001
PANSS general 36.0568.15 28.9068.21 10.14 ,0.001
BMI: body mass index; PANSS: Positive and Negative SyndromeScale.
doi:10.1371/journal.pone.0093902.t002
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to measure plasma glucose level. Triglycerides, cholesterol, LDL
and HDL levels were measured by the enzymatic colorimetric
method. Fifteen out of the 80 subjects were randomly selected for
proteomic analysis (8 females and 7 males).
Sample preparation
Venous blood (10 mL) was collected in two 5 ml BD vacutainer
between 07:00 and 08:00 to avoid circadian fluctuation of
measured parameters. One of the BD vacutainer was an EDTA
anticoagulant tube. The blood in EDTA anticoagulant tube was
centrifuged immediately after being collected. After centrifugation
(3000 rpm, 10 min), plasma was separated from the supernatant,
and then stored at 270uC for proteomic analysis. The rest 5 ml
blood was used to measure plasma levels of glucose and lipid.
Depletion of high-abundance plasma proteins
Plasma samples (500 mL) were processed to remove those most
abundant plasma proteins (i.e., albumin, IgG, IgM, IgA,
transferrin, fibrinogen, alpha2-macroglobulin, alpha1-anti-trypsin,
haptoglobin) using antibody-based immunodepletion spin columns
in accordance with the manufacturer’s protocol.
Two-dimensional gel electrophoresis
Two-dimensional gel electrophoresis was performed as de-
scribed previously [9]. Three replicates were done for each
sample. Image Master 2-D Platinum software (GE Amersham) was
used for the analysis of silver–stained gels. Each paired spot was
manually verified to ensure a high level of reproducibility between
normalized spot volumes of gel produced in triplicate data. The
overlapping measure ratio was chosen to examine change in
protein expression; a change of 1.2-fold or greater [10,11] was
considered significant.
Image analysis – determination of quantitative
differences
Protein spots were cut and destained from preparative gels.
Mass spectrography (MS) and MS/MS spectra were obtained
using the ABI 4800 Proteomics Analyzer Matrix-Assisted Laser
Desorption/Ionization Time of Flight Mass Spectrometry
(MALDI-TOF/TOF) (Applied Biosystems, Foster City, CA),
which operates in a result-dependent acquisition mode. The
GPS Explorer software (Applied Biosystems, Foster City, CA) and
MASCOT (Matrix Science, London, UK) were utilized with the
following parameter: trypsin cleavage, one missed cleavage
allowed; carbamido methylation, fixed modification; oxidation of
methionines, variable modification; peptide mass tolerance,
100 ppm; fragment tolerance, 60.3 Da. The minimum ion score
confidence interval for MS/MS data was set as 95%.
Protein identification by peptide mass fingerprinting
Acquired MS/MS spectra were searched against the NCBI
database (Dec 16th, 2006) using an in-house version of MASCOT
search engine 2.1 (Matrix Sciences, London, UK). The mass
accuracies of the precursor and fragment ions were 150 ppm and
0.7 Da, respectively. The proteins with the highest fold changes
were considered for further analysis. Using this criterion,
apolipoprotein A-1(APOPA-I) and Guanine Nucleotide Binding
Protein, Alpha Stimulating (GNAS) were selected, and were
further analyzed using enzyme linked immunosorbent assay
(ELISA) for the entire study sample to validate the results from
proteomic analysis for 15 randomly selected subjects.
Figure 1. Analysis of plasma proteins before and after
risperidone treatment using 2-DE. 1st-dimension: separation of
isoelectric focusing (IEF), immobilized pH gradient (IPG) strips PH3-10,
non-linear. 2nd-dimension: SDS-polyacrylamide gels (SDS-PAGE), 18 cm
8–16% gradient gels. Proteins were visualized using silver staining. A:
Before treatment. B: After treatment.
doi:10.1371/journal.pone.0093902.g001
Table 3. Demographic characteristics of the patients selected for gel analysis (N = 15).
Mean±SD Rage
Age(years) 2465 19–36
Disease duration (months) 1065 2–21
Age of illness onset (years) 2365 19–34
N %
Gender
Male 7 46.7
Female 8 53.3
Family history of psychiatric disorders
Yes 1 6.7
No 14 93.3
Benzodiazepine
Yes 1 6.7
No 14 93.3
doi:10.1371/journal.pone.0093902.t003
Biomarker for Side Effects in Schizophrenia
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ELISA for APOA-I and GNAS for the entire study sample
ELISA was used to measure levels of APOA-I and GNAS for all
80 subjects. The identity of subject was blinded using a code
number. Levels of APOA-I and GNAS in 100 ml medium were
measured (APOA-I: CELL BIOLABS, STA-362,detection limit:
50 pg/ml, Intra-Assay Precision 5.2%, Inter-Assay Precision
8.4%; GNAS: Antibodies-Online, ABIN840436, detection limit:
0.078 ng/ml, Intra-Assay Precision 8%, Inter-Assay Precision
10%). Duplicate samples before and after treatment were used for
quantification.
Statistical analysis
The data were analyzed using SPSS (version 17.0; SPSS Inc.,
Chicago, IL). Demographics, clinical measures and laboratory
values were reported using descriptive statistics. Group compar-
isons were performed using the Student’s t-test. Pearson correla-
tion coefficients were used to examine the relationships between
APOA-1/GNAS and other variables of interest. For all statistical
analyses, a p value of less than 0.05 (2-tailed) was used for statistical
significance.
Results
80 patients were enrolled in the study. None of them had
missing value. Demographics of the study subjects are shown in
Table 1. Clinical and laboratory measures before and after 8-week
risperidone treatments are shown in Table 2. There were
significant differences in the PANSS total and subscale scores,
body mass index, levels of triglyceride, total cholesterol and HDL
before and after treatment (p’s,0.01). However, there were no
significant differences in levels of plasma glucose and LDL before
and after treatment (p’s.0.1).
Changes in plasma proteins after risperidone treatment:
2-DE
Utilizing 2-DE, we mapped out plasma proteins individually
from blood samples obtained before and after treatment in 15
randomly selected subjects. Demographic information for the
patients selected for gel analysis was summarized in Table 3. More
than 1500 protein spots were detected and localized in the range of
pI 3–10 with a relative molecular mass of 10–70 kDa in each gel
(Figure. 1A). With initial normalization of the spot intensities and
subsequent statistical t-test analysis, 22 protein spots were found
with significant differences in abundance before and after
treatment (p’s,0.05) (Figure 1B). These 22 proteins were then
selected for MALDO-TOF/TOF analysis.
Changes in plasma proteins after risperidone treatment:
MALDI-TOF
Among 22 proteins selected by 2-DE, 18 proteins successful
passed the MALDI-TOF. There were 12 proteins up-regulated
and 6 proteins down-regulated after treatment. The name of each
protein was identified using peptide mass fingerprinting (Table 3).
From these 18 proteins, two proteins with the largest fold change
were identified: APOA-I (spot ID 2025, fold change 2.36278, up-
regulated) and GNAS (spot ID 1425, fold change 21.84374,
down-regulated) (Table 4, Figure 2).
Changes in APOA-I and GANS after risperidone
treatment: ELISA
Plasma levels of APOA-I and GNAS were measured by ELISA
for all 80 subjects before and after treatment. APOA-I was
significantly increased and GNAS was significantly decreased after
treatment (p’s,0.001); the results were consistent with the findings
obtained from the proteomic analysis (Table 5).
Relationships between changes in APOA-I, GNAS and
changes in metabolic measures over 8 weeks of
risperidone treatment
Significant positive relationships were found between changes in
APOA-I and changes in triglycerides (r = 0.350, p = 0.001), total
cholesterol (r = 0.319, p = 0.004), and BMI (r = 0.229, p = 0.041)
over 8 weeks of risperidone treatment. No significant relationships
were found between changes in APOA-1 and changes in fasting
glucose LDL or HDL (p’s.0.05). After controlling for age, gender
and family history of diabetes, the relationships between changes
in APOA-I and changes in triglycerides, total cholesterol and BMI
remain significant (p’s,0.05, Table 6). There were no significant
relationships between changes in GNAS and changes in metabolic
parameters (p’s.0.05). After controlling for age, gender and family
Figure 2. Plasma APOA-1 and GNAS expression before and
after risperidone treatment using 2-DE. A: APOA-1 (spot ID 2025)
and GNAS (spot ID 1425) expression before treatment. B: APOA-1 (spot
ID 2025) and GNAS (spot ID 1425) expression after treatment. C: Plasma
level of APOA-1 (spot ID 2025) was significantly increased after 8 weeks
of risperidone treatment. D: Plasma level of GNAS (spot ID 1425) was
significantly reduced after 8 weeks of risperidone treatment.
doi:10.1371/journal.pone.0093902.g002
Table 5. APOA-1 and GNAS measured by ELISA before and after 8 weeks of risperidone treatment (N = 80).
Before treatment After treatment t value p value
APOA-1 (mg/ml) 1.3260.22 1.7060.24 26.77 ,0.001
GNAS (ng/ml) 1.5760.003 1.5560.01 10.397 ,0.001
doi:10.1371/journal.pone.0093902.t005
Biomarker for Side Effects in Schizophrenia
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history of diabetes, there was a trend positive relationship between
changes in GNAS and changes in BMI (r = 0.211, p = 0.061,
Table 6).
Discussion
The APOA-I genes are clustered on chromosome 11q23 [12],
which has been a locus of interest in schizophrenia research
because it is near the dopamine 2 receptor (DRD2) gene [13]. To
date, the role of APOA-I in schizophrenia is not yet well defined.
Previous cross-sectional studies examined the levels of APOA-I in
schizophrenia patients with conflicting results. Decreased plasma
levels of APOA-I were found in schizophrenia [14]. Huang et al.
[15] reported that APOA-I was down-regulated in the cerebral
spinal fluid (CSF), liver, peripheral red blood cells and serum in
schizophrenia patients. However, a more recent study revealed
that APOA-I was up-regulated in the CSF of first episode patients
with schizophrenia who were on antipsychotic treatment [16]. The
heterogeneity of study samples and exposure to various antipsy-
chotic medications may explain the inconsistency in previous
findings.
In the present study, we found the plasma levels of APOA-I
were significantly increased after 8 weeks of risperidone treatment
in drug-naı¨ve, first episode schizophrenia patients. This finding is
consistent with a previous report in rats treated with antipsychotic
medication haloperidol [17]. In addition, we found that, among 80
patients with schizophrenia, the increase in APOA-I after 8 weeks
of risperidone treatment was associated with significant increases
in BMI, triglyceride and total cholesterol, independent of age,
gender, age of illness onset, family history diabetes. Our results are
consistent with previous findings from various non-psychiatric
populations [18]. APOA-I belongs to the apolipoprotein A1/A4/E
family, which is produced in the liver and small intestine [19].
APOA-I participates in the reverse transport of cholesterol from
tissues to the liver for excretion by promoting cholesterol efflux
from tissues and by acting as a co-factor for the lecithin cholesterol
acyltransferase (LCAT) [20]. APOA-I has been reported to play
an important role in lipid transportation and metabolism [21].
Consequently the up-regulation of APOA-1 may result in
increased plasma levels of cholesterols and possibly other
metabolic disturbances.
GNAS was reported to be associated with obesity and insulin
resistance [22]. The present study found a significant down-
regulation of GNAS in schizophrenia patients after 8 weeks of
risperidone treatment. However, the magnitude of change in
GNAS (about 0.8%) should be interpreted with caution in the
context of 8–10% ELISA assay precisions for GNAS. GNAS is
part of Ga, which is a subunit of heterotrimeric G-proteins.
Increased expression of G-a has been shown to activate the
adenylyl cyclase signal transduction cascade, resulting in accumu-
lation of the intracellular second messenger cyclic AMP (cAMP), a
major player in the propoptotic process [23,24]. Our study showed
a trend positive relationship between changes in GNAS and
changes in body mass index. Whether or not the down-regulation
of GNAS is related to metabolic side effects of risperidone
treatment is still unclear.
We examined the metabolic side effects of risperidone in our
study as this medication is one of the most commonly used first-
line antipsychotics used in first episode schizophrenia patients in
China. One interesting question is whether or not there is a dose-
response relationship with regard to risperidone’s metabolic side
effects, which could not be examined in our study given the
narrow dose range (4–6 mg/day) used. Further, it would be
interesting to examine the role of APOA-I and GNAS in first
episode schizophrenia treated with those antipsychotic medica-
tions that have higher risk of metabolic side effects, such as
olanzapine.
Most antipsychotic medications are associated with an increased
risk for metabolic disturbances, such as weight gain, obesity,
diabetes, hyperlipidemia, which ultimately contribute to an
increased risk for cardiovascular disease in patients with schizo-
phrenia [25]. So far there is a lack of reliable predictors for
metabolic risk in individual patients who are on antipsychotic
treatment. To our knowledge, the present study was the first to
explore potential biomarkers related to metabolic side effects of
antipsychotic treatment in first episode schizophrenia using
proteomic analysis. Our results suggest that APOA-I could be a
novel biomarker to predict metabolic side effects associated with
risperidone treatment in first episode schizophrenia.
The study has several limitations: 1) Even though we were able
to replicate the findings from a subgroup of patients (N = 15) in the
entire study sample (N = 80), it is unclear if our findings can be
replicated in a larger sample given the inherent lack of
reproducibility in proteomic studies. 2) There was no correction
for multiple testing in changes of plasma proteins after risperidone
treatment; 3) Our study did not have a control group. The use of a
more metabolically neutral antipsychotic medication as a control
arm would help determine whether the findings in our study are
specific to risperidone’s metabolic impact. 4) The study time
duration was relatively short. Despite the statistical significance in
the changes of lipid measures after 8 weeks of risperidone
treatment, the clinical significance of those changes was less
evident; clinically meaningful changes in lipids usually take longer
than 8 weeks to happen. 5) The generalizability of the findings is
Table 6. Partial correlations between changes in APOA-I, GNAS and changes in metabolic measures after controlling for age,
gender and family history of diabetes (N = 80).
APOA-1-(ELISA) GNAS-(ELISA)
r p R p
BMI (kg/m2) 0.229 0.041 0.211 0.061
blood glucose (mmol/l) 0.149 0.186 0.176 0.119
triglyceride (mmol/l) 0.350 0.001 0.096 0.396
Total cholesterol (mmol/l) 0.319 0.004 0.093 0.413
LDL (mmol/l) 0.020 0.858 20.177 0.116
HDL (mmol/l) 0.126 0.266 0.088 0.438
doi:10.1371/journal.pone.0093902.t006
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limited because only patients on risperidone were included in the
study. Future studies with a larger sample size, a well-defined
control group, a longer study time duration are need. APOA-I
could be of great clinical utility if future studies confirm that it can
predict antipsychotic-associated weight gain and other metabolic
problems, especially in those patients who are on antipsychotic
medications that carry a higher metabolic risk, such as olanzapine
or clozapine.
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